论文部分内容阅读
目的分析吉西他滨为基础的化疗方案治疗进展期胰腺癌的临床疗效。方法选取在2014年1月至2015年6月期间到我院接受化疗的进展期胰腺癌患者54例,其中21例患者接受吉西他滨单药化疗,将其作为对照组;33例患者接受吉西他滨联合其他药物化疗,将其作为观察组。比较两组患者的临床疗效、生存情况及不良反应。结果观察组患者临床有效率为42.4%,疾病控制率为81.8%,对照组临床有效率为19.0%,疾病控制率为52.4%,两组差异有统计学意义(P<0.05)。两组中位生存时间分别为11.7个月和7.1个月,中位无进展生存时间分别为4.6个月和2.8个月,6个月生存率分别为69.7%和57.1%,两组比较,差异具有统计学意义(P<0.05);观察组对CA199水平的影响优于对照组(P<0.05);两组不良反应比较,差异无统计学意义(P>0.05)。结论以吉西他滨为基础的化疗方案治疗进展期胰腺癌,较单药治疗效果更佳,可显著提高患者生存率。
Objective To analyze the clinical efficacy of gemcitabine-based chemotherapy in the treatment of advanced pancreatic cancer. Methods Fifty-four patients with advanced pancreatic cancer who received chemotherapy in our hospital from January 2014 to June 2015 were selected, of whom 21 received gemcitabine monotherapy as control group and 33 received gemcitabine combined with other Drug chemotherapy, as the observation group. The clinical efficacy, survival and adverse reactions of the two groups were compared. Results The clinical effective rate was 42.4% in the observation group, the disease control rate was 81.8%, the clinical effective rate in the control group was 19.0% and the disease control rate was 52.4%. There was significant difference between the two groups (P <0.05). The median survival time was 11.7 months and 7.1 months respectively. The median progression-free survival time was 4.6 months and 2.8 months respectively. The 6-month survival rates were 69.7% and 57.1% respectively. There was significant difference between the two groups (P <0.05). The effect of observation group on CA199 level was better than that of control group (P <0.05). There was no significant difference between the two groups in adverse reactions (P> 0.05). Conclusion The gemcitabine-based chemotherapy regimen for advanced pancreatic cancer is more effective than monotherapy, which can significantly improve the survival rate of patients.